AstraZeneca expects COVID-19 phase 3 trial results 'later this year' after pause

AstraZeneca announced Wednesday that it still expects results from phase three of its COVID-19 vaccine trial to be ready by the end of 2020.
The deal to unite the two Italian brands has an estimated value of $1.36bn (£1.06bn). from BBC News https://ift.tt/IF1bAUd
0 comments:
Post a Comment